Search academic texts

Information × Registration Number 0214U007167, 0111U001883 , R & D reports Title Development and pharmacological study of Ukraine's first anticytokine drug - recombinant receptors antagonist interleukin-1 and determine ation of the prospects of its use in clinic of organ disorders popup.stage_title Head Drogovoz Svetlana Mefodyevna, Registration Date 05-05-2014 Organization Nation University of Pharmacy popup.description2 Object of study - a recombinant receptor antagonist of interleukin -1 ( aryl -1). The purpose of the study - creation and pharmacological study of the first in Ukraine drug mechanism of action aimed at blocking the synthesis and action of interleukin -1 ( IL -1) , which will translate the therapy of many diseases to a new level . Research methods - pharmacological , biochemical , histological , and statistical . The results of researches show that in models of acute aseptic inflammation aryl -1 exhibits antiexudativ properties antialterativnuyu activity on the level of diclofenac sodium . Expressive antiproliferative effect aryl -1 indomethacin is not inferior . Aryl exhibits moderate analgesic properties, and its degree of antipyretic activity depends on the input mode . Aryl -1 has pronounced cardioprotective , hepatoprotective , antioxidant and immunotropic properties. Also aryl -1 has cerebroprotective, hypoxic, antidepressant , anticonvulsant and antiamnesic action. Determined that the aryl -1 significantly attenuates the toxic effects of ethanol on the brain of experimental animals. The studies proved the feasibility of further experimental study aryl -1 for use in the treatment of inflammatory diseases, autoimmune diseases , cerebral insufficiency of various origins .5481 Product Description popup.authors Белік Г.В. Кононенко Г.В. Щокіна К.Г. popup.nrat_date 2020-04-02 Close